July 08, 2015
The first half of 2015 was action-packed with rulings on key pharmaceutical antitrust issues and agency wins in high-profile challenges, but there's still plenty to watch for over the next six months, including cases that could alter the landscape of college sports and professional baseball and major challenges to benchmark banking rates.
April 22, 2015
Rite Aid Corp., Walgreen Co. and others on Wednesday reinforced their push to consolidate pending appeals in the Lipitor and Effexor XL pay-for-delay suits, arguing that a single Third Circuit panel review is the fairest, most economical approach.
April 17, 2015
Pfizer Inc. and Ranbaxy Inc. on Thursday urged the Third Circuit to reject a bid by Rite Aid Corp., Walgreen Co. and other retailers to consolidate all pending appeals in the Lipitor and Effexor XP pay-for-delay litigations, saying the cases are far too different to consolidate.
April 03, 2015
Rite Aid Corp., Walgreen Co. and other retailers asked the Third Circuit on Friday to consolidate all pending appeals in the Effexor XR and Lipitor pay-for-delay litigations, saying it would conserve resources given the similarities in the legal issues raised and overlap of parties and counsel.